

# Susan S Ellenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3527647/publications.pdf>

Version: 2024-02-01

72  
papers

4,267  
citations

212478

28  
h-index

129628

63  
g-index

102  
all docs

102  
docs citations

102  
times ranked

4802  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving the Approach to Defining, Classifying, Reporting and Monitoring Adverse Events in Seriously Ill Older Adults: Recommendations from a Multi-stakeholder Convening. <i>Journal of General Internal Medicine</i> , 2023, 38, 399-405.	1.3	1
2	Physical Activity and Its Association with Traditional Outcome Measures in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2022, 19, 572-582.	1.5	6
3	Relation of Testosterone, Dihydrotestosterone, and Estradiol With Changes in Outcomes Measures in the Testosterone Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1257-1269.	1.8	8
4	Determinants of hospital outcomes for patients with COVID-19 in the University of Pennsylvania Health System. <i>PLoS ONE</i> , 2022, 17, e0268528.	1.1	3
5	Pain, Analgesic Use, and Patient Satisfaction With Spinal Versus General Anesthesia for Hip Fracture Surgery. <i>Annals of Internal Medicine</i> , 2022, 175, 952-960.	2.0	22
6	Early Termination of Clinical Trials for Futility – Considerations for a Data and Safety Monitoring Board. , 2022, 1, .		3
7	Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 517-523.	1.3	2
8	Prediction of postvaccination Guillain-Barré syndrome using data from a passive surveillance system. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 602-609.	0.9	7
9	Monitoring vaccine safety by studying temporal variation of adverse events using vaccine adverse event reporting system. <i>Annals of Applied Statistics</i> , 2021, 15, .	0.5	3
10	Blinding in Clinical Trials for Chronic Liver Diseases. <i>Seminars in Liver Disease</i> , 2021, 41, 163-171.	1.8	1
11	Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials. <i>Journal of Infectious Diseases</i> , 2021, 224, 1995-2000.	1.9	19
12	Rejoinder. <i>Statistics in Medicine</i> , 2021, 40, 2536-2539.	0.8	1
13	AIDS and COVID: A tale of two pandemics and the role of statisticians. <i>Statistics in Medicine</i> , 2021, 40, 2499-2510.	0.8	9
14	Monitoring clinical trials in infectious diseases. , 2021, 2, 29-32.		0
15	Spinal Anesthesia or General Anesthesia for Hip Surgery in Older Adults. <i>New England Journal of Medicine</i> , 2021, 385, 2025-2035.	13.9	211
16	Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study. <i>Gastroenterology</i> , 2020, 158, 527-536.e7.	0.6	171
17	Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2142-2149.	1.8	4
18	Real-world experiences with generating real-world evidence: Case Studies from PCORI's pragmatic clinical Studies program. <i>Contemporary Clinical Trials</i> , 2020, 98, 106171.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals. <i>Clinical Trials</i> , 2020, 17, 552-559.	0.7	3
20	Clinical trials in the time of a pandemic. <i>Clinical Trials</i> , 2020, 17, 467-471.	0.7	5
21	Markers of Iron Flux during Testosterone-Mediated Erythropoiesis in Older Men with Unexplained or Iron-Deficiency Anemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3396-3403.	1.8	7
22	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. <i>Pain</i> , 2020, 161, 2446-2461.	2.0	64
23	Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential. <i>Lancet</i> , The, 2020, 396, 1611-1613.	6.3	7
24	Aggregating data from COVID-19 trials. <i>Science</i> , 2020, 368, 1198-1199.	6.0	7
25	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. <i>New England Journal of Medicine</i> , 2020, 382, 1366-1369.	13.9	63
26	Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6238-6246.	1.8	20
27	Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Liver Transplantation</i> , 2019, 25, 1155-1164.	1.3	26
28	Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol. <i>BMJ Open</i> , 2019, 9, e025556.	0.8	60
29	Data Monitoring Committees: Current issues. <i>Clinical Trials</i> , 2018, 15, 321-328.	0.7	29
30	Considerations for analysis of time-to-event outcomes subject to competing risks in veterinary clinical studies. <i>Journal of Veterinary Cardiology</i> , 2018, 20, 143-153.	0.3	6
31	Rigorous Clinical Trial Design in Public Health Emergencies Is Essential. <i>Clinical Infectious Diseases</i> , 2018, 66, 1467-1469.	2.9	20
32	Reply to Jacob and Colebunders. <i>Clinical Infectious Diseases</i> , 2018, 67, 985-986.	2.9	0
33	The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 681-688.	1.8	79
34	The Stepped-Wedge Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 607.	3.8	21
35	Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 879-890.	5.5	64
36	Comparison of nuisance parameters in pediatric versus adult randomized trials: a meta-epidemiologic empirical evaluation. <i>BMC Medical Research Methodology</i> , 2018, 18, 7.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Expedited approval programs at the Food and Drug Administration. <i>Clinical Trials</i> , 2018, 15, 217-218.	0.7	1
38	Lessons From the Testosterone Trials. <i>Endocrine Reviews</i> , 2018, 39, 369-386.	8.9	173
39	Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 708.	3.8	289
40	Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 717.	3.8	179
41	Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone. <i>JAMA Internal Medicine</i> , 2017, 177, 471.	2.6	241
42	Association of Testosterone Levels With Anemia in Older Men. <i>JAMA Internal Medicine</i> , 2017, 177, 480.	2.6	180
43	Changes in Coronary Artery Plaque With Testosterone Therapyâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2451.	3.8	4
44	Data monitoring committees: Promoting best practices to address emerging challenges. <i>Clinical Trials</i> , 2017, 14, 115-123.	0.7	61
45	Meta-Epidemiology of Testosteroneâ€™s Risks and Benefitsâ€™Will We Ever Know the Answer?â€™Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 1392.	2.6	0
46	Discussion: Is the FDA in need of a major change in the way it regulates?. <i>Biostatistics</i> , 2017, 18, 414-416.	0.9	1
47	A signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system data. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 76.	1.5	12
48	Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach. <i>Trials</i> , 2017, 18, 474.	0.7	5
49	Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3096-3104.	1.8	110
50	Regional versus General Anesthesia for Promoting Independence after Hip Fracture (REGAIN): protocol for a pragmatic, international multicentre trial. <i>BMJ Open</i> , 2016, 6, e013473.	0.8	70
51	Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. <i>AJOB Empirical Bioethics</i> , 2016, 7, 106-115.	0.8	16
52	Data Monitoring Committees â€™ Expect the Unexpected. <i>New England Journal of Medicine</i> , 2016, 375, 1365-1371.	13.9	46
53	Cognitive Effects of Adenotonsillectomy for Obstructive Sleep Apnea. <i>Pediatrics</i> , 2016, 138, .	1.0	67
54	Evaluating interventions for Ebola: The need for randomized trials. <i>Clinical Trials</i> , 2016, 13, 6-9.	0.7	13

#	ARTICLE	IF	CITATIONS
55	Effects of Testosterone Treatment in Older Men. <i>New England Journal of Medicine</i> , 2016, 374, 611-624.	13.9	675
56	Recruitment and Screening for the Testosterone Trials. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 1105-1111.	1.7	28
57	The Use of Clinical Parameters to Predict Obstructive Sleep Apnea Syndrome Severity in Children. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 130.	1.2	122
58	Prognosis for Spontaneous Resolution of OSA in Children. <i>Chest</i> , 2015, 148, 1204-1213.	0.4	87
59	Data monitoring committees for pragmatic clinical trials. <i>Clinical Trials</i> , 2015, 12, 530-536.	0.7	32
60	Utility of Symptoms to Predict Treatment Outcomes in Obstructive Sleep Apnea Syndrome. <i>Pediatrics</i> , 2015, 135, e662-e671.	1.0	92
61	Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 1966-1974.	6.3	282
62	Commentary on Hey and Kimmelman. <i>Clinical Trials</i> , 2015, 12, 116-118.	0.7	14
63	The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. <i>Clinical Trials</i> , 2014, 11, 362-375.	0.7	98
64	A trial of in-hospital, electronic alerts for acute kidney injury: Design and rationale. <i>Clinical Trials</i> , 2014, 11, 521-529.	0.7	11
65	Investigators'™ Experience With Expedited Safety Reports Prior to the FDA's™ Final IND Safety Reporting Rule. <i>Therapeutic Innovation and Regulatory Science</i> , 2014, 48, 413-419.	0.8	4
66	Predicting Survival in Non-™Small-Cell Lung Cancer Using Positron Emission Tomography: Several Conclusions From Multiple Comparisons. <i>Journal of Clinical Oncology</i> , 2014, 32, 1631-1632.	0.8	6
67	Protecting Clinical Trial Participants and Protecting Data Integrity: Are We Meeting the Challenges?. <i>PLoS Medicine</i> , 2012, 9, e1001234.	3.9	15
68	Current issues in clinical trials: standing on the shoulders of Jerome Cornfield. <i>Statistics in Medicine</i> , 2012, 31, 2798-2804.	0.8	1
69	Registration of epidemiological studies: benefits and risks. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1005-1008.	0.9	0
70	The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trials. <i>Contemporary Clinical Trials</i> , 1995, 16, 408-421.	2.0	65
71	Statistical Issues Arising in AIDS Clinical Trials. <i>Journal of the American Statistical Association</i> , 1992, 87, 562-569.	1.8	34
72	Design Considerations for AIDS Trials. <i>New England Journal of Medicine</i> , 1990, 323, 1343-1348.	13.9	149